Drug Profile
PE 0139
Alternative Names: Insumera; PE 0139Latest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator PhaseBio Pharmaceuticals
- Class Antihyperglycaemics; Biopolymers; Drug conjugates; Insulins; Pancreatic hormones; Recombinant fusion proteins
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 28 Sep 2021 Discontinued - Phase-II for Type 2 diabetes mellitus in USA (SC) before September 2021 (PhaseBio Pharmaceuticals' pipeline, September 2021)
- 07 Dec 2018 PE 0139 is still in phase II trials for Type 2 diabetes mellitus in USA (PhaseBio Pharmaceuticals pipeline, November 2018)
- 01 Nov 2016 PhaseBio Pharmaceuticals completes a phase II trial in Type-2 diabetes mellitus in USA (NCT02581657)